|1.||Keith, James C: 5 articles (01/2011 - 07/2003)|
|2.||Keith, J C: 5 articles (10/2001 - 08/2000)|
|3.||Nichols, Timothy C: 3 articles (02/2013 - 07/2003)|
|4.||Merricks, Elizabeth P: 3 articles (02/2013 - 07/2003)|
|5.||Ragni, Margaret V: 2 articles (02/2013 - 10/2011)|
|6.||Kloos, Mark T: 2 articles (02/2013 - 10/2011)|
|7.||Sekine, Ichiro: 2 articles (03/2007 - 04/2003)|
|8.||Shichijo, Kazuko: 2 articles (03/2007 - 04/2003)|
|9.||Nakayama, Toshiyuki: 2 articles (03/2007 - 04/2003)|
|10.||Pollack, Matthew: 2 articles (01/2007 - 06/2005)|
10/01/2015 - "[Therapeutic Efficacy of Multigly-Cosidorum Tripterygium Combined with rhIL-11 for Immune Thrombocytopenia]."
03/07/2001 - "These results suggest that rhIL-11 ameliorates the thrombocytopenia via the stimulation of both the maturation and commitment followed by the proliferation of megakaryocytic cells."
05/01/2003 - "The mean duration of thrombocytopenia (< 100 x 10(9)/L) in rhIL-11 treated cycle was 1.0 +/- 2.0 days as compared to 6.9 +/- 5.3 days in placebo treated cycle. "
10/01/2002 - "This observation suggests that oprelvekin might be crucial in the acute management of certain types of hypersplenic thrombocytopenias."
08/01/2002 - "In conclusion, the rhIL-11 (Mega) could be used as an effective drug for treatment of thrombocytopenia in CAA patients."
02/01/2005 - "The disk edema resolved with discontinuation of oprelvekin therapy. "
08/01/2000 - "Histologically, treatment of rhIL-11 reduced the severity of pancreatic injury including edema, inflammatory cell infiltration, and hemorrhage at 6 hours. "
09/01/2007 - "IFS- induced macroscopic edema and hemorrhage and microscopic alterations, were also prevented by rhIL-11 at 625 microg. "
01/01/1998 - "Generally mild edema and minor conjunctival bleeding (grades 1 or 2) were statistically associated with rhIL-11 administration (p < 0.04). "
09/01/2000 - "However, these adverse events can be medically managed and need not limit the use of rhIL-11, particularly if ameliorative measures, such as salt restriction and occasional prophylaxis with a potassium-sparing diuretic to minimize peripheral edema, have been instituted along with close monitoring of fluid and electrolyte status. "
|3.||Crohn Disease (Crohn's Disease)
03/01/2002 - "To determine the safety and preliminary estimate of efficacy of rhIL-11 in treating active Crohn's disease. "
07/01/1999 - "The objectives of this study were to investigate the safety and tolerability of rhIL-11 in patients with Crohn's disease and to explore the effects of dose and schedule on platelet count and Crohn's disease activity. "
12/01/1997 - "Based on these studies, rhIL-11 is currently in clinical trials for treatment of Crohn's disease. "
07/01/1999 - "The thrombocytopoietic effect of rhIL-11 seems to be both dose and schedule dependent and may be minimized with retained clinical benefit in Crohn's disease at 16 microgram. "
07/01/1999 - "Short-term treatment with rhIL-11 is well tolerated in patients with active Crohn's disease. "
05/15/1999 - "The potential efficacy of combination therapy with recombinant human forms of rhIL-11 and rhG-CSF was studied in a neutropenic rat model of Pseudomonas aeruginosa sepsis. "
05/15/1999 - "These results indicate that the combination of rhIL-11 and rhG-CSF is additive as a treatment strategy in the prevention and treatment of experimental Gram-negative sepsis in immunocompromised animals. "
01/01/1996 - "We next investigated the prophylactic effect of rhIL-11 on the PLT recovery as well as survival in NR during experimental GBS sepsis. "
01/01/1996 - "Furthermore, prophylactic administration of pharmacological doses of rhIL-11 may be potentially beneficial in the management of neonatal GBS sepsis and its associated thrombocytopenia. "
12/01/1997 - "rhIL-11 increased survival in models of Gram-negative sepsis and toxic shock. "
|5.||Radiation Injuries (Radiation Sickness)
10/01/2007 - "These data show that local administration of rhIL-11 ameliorates early intestinal radiation injury and support further development of rhIL-11 to reduce manifestations of intestinal radiation injury in the clinic."
03/01/2007 - "These results suggest that rhIL-11 may play an important role in protection from radiation injury."
05/01/2015 - "These results suggest that the combined administration of SNP, WR-2721, rhIL-11 and rhG-CSF should increase the efficacy of these drugs for acute radiation sickness, protect immunity, hematopoiesis and the reproductive organs of irradiated-damaged mice, and improve oxidation resistance in the body. "
10/01/2007 - "rhIL-11 ameliorated structural manifestations of radiation enteropathy, including radiation injury score (6.5 +/- 0.6 in the vehicle group versus 4.0 +/- 0.3 in the IL-11 group; P = 0.001), mucosal surface area loss (0.2 +/- 0.1 versus 0.5 +/- 0.03; P < 0.0001), and intestinal wall thickening (842 +/- 66 microm versus 643 +/- 54 microm; P = 0.02), reduced postradiation transforming growth factor-beta overexpression, and reduced numbers of ED2-positive cells. "
|1.||Interleukin-11 (Interleukin 11)
|2.||Inosine Triphosphate (ITP)
|3.||HLA-B27 Antigen (HLA B27 Antigen)
|4.||Messenger RNA (mRNA)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|8.||Interleukin-12 (IL 12)
|9.||Interleukin-6 (Interleukin 6)
|1.||Drug Therapy (Chemotherapy)
|2.||Platelet Transfusion (Blood Platelet Transfusions)
|5.||Bone Marrow Transplantation (Transplantation, Bone Marrow)